This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the recently released data from the ongoing Phase 2 open-label extension clinical trial of donidalorsen in patients with Hereditary Angioedema

Ticker(s): IONS

Who's the expert?

 

  • Allergy and Immunology Specialist at Olean Medical Group.
  • Currently manages 12 patients with Hereditary Angioedema.
  • Familiar with Phase 3 KONFIDENT Trial regarding Sebetralstat.

Interview Goal
to discuss the current standard of care and the potential of donidalorsen, an investigative prophylactic medicine being developed by Ionis Pharma to prevent HAE attacks.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.